Elanco's (ELAN) ZORBIUM Approved in the US

With the U.S. Food and Drug Administration (FDA) approval of Zorbium™ (buprenorphine transdermal solution), Elanco Animal Health (NYSE: ELAN) expands its pain management offerings while addressing an unmet need for veterinary practices.

A new long-acting medication to control postoperative pain associated with surgical procedures in cats, ZORBIUM provides up to four days of pain control from a single transdermal dose. ZORBIUM is an innovative, transdermal formulation of a commonly used opioid (buprenorphine) in cats, enabling veterinarians to provide consistent, reliable pain relief to their post-op feline patients for 4 days without relying upon owners to administer an opioid after discharge and without the need for repeat injections. Consistent pain control reassures cat owners and reduces the challenges of administering pain medications at home.

“The simplification of dosing helps limits the movement of opioids, which can give clinics and pet parents alike peace of mind,” said Dr. Ellen de Brabander, executive vice president of Innovation and Regulatory Affairs at Elanco “The needleless transdermal application is met with sustained pain control, avoiding the potential for missed doses associated with repeat dosing protocols.”

Elanco’s first new product approval of 2022, Zorbium™ is anticipated to reach the U.S. veterinary community mid-year.

ZORBIUM represents an important milestone in the continued diversification of Elanco’s portfolio and pipeline. Last month, Elanco announced measures to transform and simplify its R&D organization to narrow focus and concentrate investments on accelerating delivery of the late-stage Pet Health pipeline.

“Elanco has long been an innovation leader in pain management in pets, and this approval is a perfect example of Elanco’s capabilities meeting the science and the market need,” de Brabander said.

You May Also Be Interested In

• Bristol-Myers Squibb (BMY) Provides Update on Phase 3 CheckMate -73L Trial
• Orthofix International (OFIX) Announces FDA 510(k) Clearance for the Rodeo Telescopic Nail
• Revance Therapeutics (RVNC) Expands into US Market with the Launch of DAXXIFY